Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

MUSTANG BIO, INC.

  • WALTHAM, Massachusetts
  • Public · NASDAQ: MBIO
  • 4 employees
$5.1MMarket cap
$0Revenue · FY2019
-$1.9MNet income
4Employees
MBIONASDAQ
2017IPO

About MUSTANG BIO, INC.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2019
$0
Net income
-$1.9M
Total assets
$17.6M
Market cap
$5.1M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: MBIO

15-minute delayed · data by Polygon.io

Market cap
$5.1M
Open
Day range
Prev close
Volume
IPO date
Aug 22, 2017

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review MUSTANG BIO, INC..

Write a review
Explore

Similar companies

Browse all →